Work

Abstract CT220: A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Interim efficacy subset analyses

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct220

Authors: Daniel Flora, Ari Baron, Reema Patel, Davendra Sohal, Saima Sharif, Fa Chyi Lee, Julie Anne Gemmill, Gilles H. Tapolsky, James Beach, Michael Gazda, Tariq Arshad

Institutions: St. Elizabeth Healthcare, University of Kentucky, University of Cincinnati, University of Iowa, University of California, Irvine, Stony Brook University, Bexion Pharmaceuticals (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154688230

Cites:

Cited by:

Related to: